Needle-Free Drug Injection Systems and Safety Syringes: The Market for Alternatives to Traditional Needle-Based Delivery

Table of Contents

• Chapter One: Executive Summary
  • 1.1 Background and Perspective
  • 1.2 Traditional Drug Delivery Systems
  • 1.3 Need for Alternative Delivery Systems
  • 1.4 Market Summary
    • 1.4.1 Market Drivers
    • 1.4.2 Market Challenges
    • 1.4.3 Brief Market Forecast
  • 1.5 Methodology
• Chapter Two: Introduction
  • 2.1 Risk and Prevention
  • 2.2 Overview of Different Drug Delivery Systems
    • 2.2.1 Polymers and Biomaterials
    • 2.2.2 Oral Drug Delivery Systems
    • 2.2.3 Pulmonary Drug Delivery
    • 2.2.4 Drug Eluting Stents
    • 2.2.5 Percutaneous Drug Delivery
    • 2.2.6 Ophthalmic Drug Delivery
    • 2.2.7 Colloidal Drug Delivery
    • 2.2.8 Site Specific Delivery
    • 2.2.9 Needle-Free Delivery
    • 2.2.10 Safety Syringes
  • 2.3 Key Medicines for Delivery
    • 2.3.1 Insulin
    • 2.3.2 Human Growth Hormone
    • 2.3.3 Vaccines
  • 2.4 Alternatives to Needle Delivery of Drugs
    • 2.4.1 Needle-Free Systems
    • 2.4.2 Safety Syringes
  • 2.5 Factors Driving Development
    • 2.5.1 Epidemiology of Injuries
    • 2.5.1 Epidemiology of Bloodborne Virus Transmission
      • 2.5.1.1 Hepatitis B Virus
      • 2.5.1.2 Hepatitis C Virus
      • 2.5.1.3 HIV
    • 2.5.3 Cost of Needlestick Injuries
    • 2.5.4 Prevention Approaches
  • 2.6 Challenges and Issues
  • 2.7 Needle-Free and Safety Syringe Drug Delivery Research
    • 2.7.1 Microscission
    • 2.7.2 Evolving Vaccine Delivery Technologies
      • 2.7.2.1 Auto-Disable Syringes
      • 2.7.2.2 Monodose Prefilled Injection Devices
      • 2.7.2.3 Needle-Free Injections
      • 2.7.2.4 Thermostable Vaccines
• Chapter Three: Markets
  • 3.1 Current Face of the Market
    • 3.1.1 Safety and Cost as Major Drivers
    • 3.1.2 Technology Development
    • 3.1.5 Prefilled Devices and Non-Prefilled Devices.
    • 3.1.4 Convenience and Compliance
    • 3.1.5 Product Differentiation
    • 3.1.6 Harm Reduction.
    • 3.1.7 Opportunity
  • 3.2 Human Growth Hormone
  • 3.3 Insulin
  • 3.4 Vaccines
    • 3.4.1 Immunization Programs
    • 3.4.2 Emerging Vaccines
    • 3.4.3 Injection Concerns
  • 3.5 Needlestick Injuries
  • 3.6 Geographic Markets
• Chapter Four: Corporate Profiles
  • 4.1 Antares Pharma Inc.
  • 4.2 Aradigm Corp.
  • 4.3 Becton, Dickinson and Co.
  • 4.4 Bioject Medical Technologies Inc.
  • 4.5 BioValve Technologies Inc.
  • 4.6 Cambridge Biostability Ltd.
  • 4.7 D'Antonio Consultants International
  • 4.8 Eastland Medical Systems Ltd.
  • 4.9 Equidyne Systems
  • 4.10 First Principals Inc.
  • 4.11 Med-Design Corp.
  • 4.12 Medical House PLC
  • 4.13 Medical International Technologies
  • 4.14 Medisys PLC
  • 4.15 National Medical Products Inc.
  • 4.16 New Medical Technology
  • 4.17 Norwood Abbey Ltd.
  • 4.18 Retractable Technologies Inc.
  • 4.19 Roche (F. Hoffmann-La Roche Ltd.)
  • 4.20 Serono Inc.
  • 4.21 Safety Syringes Inc.
  • 4.22 Smiths Medical (Smiths Group)
  • 4.23 Sunder Group
  • 4.24 Tyco Healthcare
  • 4.25 Unilife Medical Solutions Ltd.
  • 4.26 Univec Ltd.
• List Of Exhibits
• Chapter One: Executive Summary
  • Exhibit 1-1: Summary: World Market for Drugs Delivered by Needle-Free Systems 2005-2009
  • Exhibit 1-2: Summary: World Market for Needle-Free Drug Injectors 2005-2009
  • Exhibit 1-3: World Market for Safety Syringes 2005-2009
• Chapter Two: Introduction
  • Exhibit 2-1: Immunization Cost Analysis
  • Exhibit 2-2: Adult Preventable Disease Statistics
  • Exhibit 2-3: Advantages of Needle-Free Delivery
  • Exhibit 2-4: Annual Injury Rates for Healthcare and Sanitary Service Personnel from Sharps in Found Medical Waste
  • Exhibit 2-5: Work Locations Where Fluid Exposures Occurred (NaSH 6/95 to 10/01)
  • Exhibit 2-6: Circumstances Associated with Hollow-Bore Needle Injuries (NaSH 6/95 to 12/01)
  • Exhibit 2-7: Devices Involved in Percutaneous Injuries (NaSH)
  • Exhibit 2-8: Infections Transmitted via Sharps, Injuries during Patient Care and/or Laboratory/Autopsy
  • Exhibit 2-9: Estimated Number of People Living with HIV 2000-2004
• Chapter Three: Markets
  • Exhibit 3-1: Prevalence of Diabetes in the Seven Major World Healthcare Markets by Type 2004-2014
  • Exhibit 3-2: World Market for Syringes Dollar Volume 2005-2009
  • Exhibit 3-3: World Market for Syringes Dollar Volume by Geographic Region 2005-2009
  • Exhibit 3-4: World Market for Syringes Unit Sales 2005-2009
  • Exhibit 3-5: World Market for Syringes Unit Sales by Geographic Region 2005-2009
  • Exhibit 3-6: World Market for Safety Syringes Dollar Volume 2005-2009
  • Exhibit 3-7: World Market for Safety Syringes Dollar Volume by Geographic Region 2005-2009
  • Exhibit 3-8: World Market for Safety Syringes Unit Sales 2005-2009
  • Exhibit 3-9: World Market for Safety Syringes Unit Sales by Geographic Region 2005-2009
  • Exhibit 3-10: Market Segments for Safety Syringes Percentage by Distribution Channel
  • Exhibit 3-11: Worldwide Safety Syringe Market Market Share of Leading Competitors
  • Exhibit 3-12: World Market for Drugs Delivered by Needle-Free Systems 2005-2009
  • Exhibit 3-13: World Market for Needle-Free Drug Injectors Dollar Volume 2005-2009
  • Exhibit 3-14: World Market for Needle-Free Drug Injectors Dollar Volume by Geographic Region 2005-2009
  • Exhibit 3-15: World Market for Needle-Free Drug Injectors Unit Sales 2005-2009
  • Exhibit 3-16: World Market for Needle-Free Drug Injectors Unit Sales by Geographic Region 2005-2009
  • Exhibit 3-17: Status of Selected Needle-Free Injection Systems and Safety Syringes